Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01526837
Recruitment Status : Terminated (Investigators decision)
First Posted : February 6, 2012
Last Update Posted : July 12, 2017
Information provided by (Responsible Party):
John Abrahams, M.D., Brain & Spine Surgeons of New York

Brief Summary:
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Avastin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Study Start Date : October 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: bevacizumab (Avastin)
Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
Drug: Avastin
Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.

Primary Outcome Measures :
  1. Maximum Tolerated Dose of bevacizumab (Avastin) following local administration. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Number of Adverse Events [ Time Frame: 12 months ]
    All adverse events will be recorded in the case report form.

  2. Progression Free Survival [ Time Frame: 12 months ]
    Patients will be followed for survival as well as disease progression for 12 months after treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Recurrent Glioblastoma
  2. At least 12 weeks expected survival (KPS >60)
  3. 18 years of age or older
  4. Able and willing to participate

Exclusion Criteria:

  1. Any prior diagnosis of any other cancer or other concurrent malignancy.
  2. Planned use or current use of other investigation therapy.
  3. Systemic autoimmune disease
  4. HIV positive
  5. Concurrent life threatening disease
  6. Impaired organ function
  7. Active infection
  8. Inadequately controlled hypertension
  9. Congestive heart failure
  10. Myocardial infection/unstable angina within 6 months
  11. Stroke within 6 months
  12. Pheripheral vascular disease
  13. History of abdominal fistula/gastrointestinal performation
  14. Non-healing wound
  15. Coagulation disease
  16. Known allergy to study treatments
  17. Pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01526837

Layout table for location information
United States, New York
Brain & Spine Surgeons of New York
White Plains, New York, United States, 10604
Sponsors and Collaborators
Brain & Spine Surgeons of New York
Layout table for investigator information
Principal Investigator: John Abrahams, MD Brain & Spine Surgeons of New York
Study Director: Jan Strack BSSNY
Layout table for additonal information
Responsible Party: John Abrahams, M.D., Associate Professor of Neurosurgery, Brain & Spine Surgeons of New York Identifier: NCT01526837    
Other Study ID Numbers: BSSNY-B-001
First Posted: February 6, 2012    Key Record Dates
Last Update Posted: July 12, 2017
Last Verified: July 2017
Keywords provided by John Abrahams, M.D., Brain & Spine Surgeons of New York:
Brain tumor
Brain cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Disease Attributes
Pathologic Processes
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors